'Transformational' time for newly-enlarged company that embodies regenerative medicine's burgeoning potential, CEO says

25 August 2017

Antony Odell, chief executive of UK-based regenerative medicine company Tissue Regenix (AIM: TRX), is honest about the industry’s mixed fortunes so far when it comes to turning talk about regenerative medicine into effective products.

“There was a silly period, like the dot com boom, when everyone pumped money into very early-stage technologies,” he says. “But I think it’s come of age and what you have now is a smaller number of more mature companies that are focused on delivering products to market.”

"I think we will show that you can take one of these companies from scratch and get it profitable"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK